RusnanoMedInvest, a subsidiary of the state-run Russian investment firm Rusnano, has led a $51m Series E round into Regado Biosciences, a thrombosis treatment company.
There was also participation from new investor Baxter Healthcare’s venture initiative, Baxter Ventures. Existing investors private equity firm Edmond de Rothschild Investment Partners and venture capital firms Domain Associates, Quaker Partners, Aurora Funds and Caxton Advantage Life Sciences Fund were also involved.
David J. Mazzo, President and Chief Executive of Regado, said: “We welcome new investors RusnanoMedInvest and Baxter Ventures as we advance REG1 into Phase 3 development. We also thank our existing investors for their continued confidence in our execution strategy and shared enthusiasm for uncovering REG1’s full potential. We believe the magnitude of this investment and our continued ability to attract new investors is a testament to the outstanding clinical results and potential game-changing therapeutic value we have demonstrated to date for REG1.”
The new funds will be used to support Regado’s “REGULATE – PCI” Phase 3 clinical study of REG1, the company’s lead development program for REG1 in arterial thrombosis, and develop other programs in the Regado pipeline such as REG1 for TAVI (transaortic valve implantation) and REG3 in diabetic vasculopathy.
In 2009 Regado raised $40m in a Series D round from Edmond de Rothschild Venture Capital, Domain Associates, Quaker BioVentures, The Aurora Funds and Caxton Advantage Life Sciences Fund.